Key facts
- This page summarizes Christopher E. Kevane's Form 4 filing for UNIVERSAL TECHNICAL INSTITUTE INC (UTI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2021, 16:08.
Christopher E. Kevane - 08 Dec 2021 Form 4 Insider Report for UNIVERSAL TECHNICAL INSTITUTE INC (UTI)
- Reporting relationship
- SVP Chief Legal Officer
- Issuer ticker
- UTI
- Reported as of
- 08 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 16:08:31 UTC
- Next SEC filing
- 17 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher E. Kevane
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher E. Kevane filed Form 4 for UNIVERSAL TECHNICAL INSTITUTE INC (UTI) on 10 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
UTI
transaction
Derivative
Performance Units
Award
- Transaction value
- $0
- Shares
- +36,336
- Change %
- +61%
- Price
- $0.000000
- Shares after
- 95,875
- Date
- 08 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 36,336
- Exercise price
- Footnotes
- F1
UTI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +19,379
- Change %
- +68%
- Price
- $0.000000
- Shares after
- 47,808
- Date
- 08 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 19,379
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2024 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2024, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.
Footnote F3
The restricted stock units vest in three equal annual installments beginning on December 8, 2022.